Literature DB >> 11357240

Botulinum toxin: evidence-based medicine criteria in rare indications.

W H Jost1, A Kohl.   

Abstract

Presently, there are more than 50 possible indications for the application of botulinum toxin. In some indications the use of botulinum toxin has already been approved; others are about to be approved. For most of these indications a sufficient number of studies have been published. For rare indications, an insufficient number of studies are available. In part there are only published case reports. Classification according to the criteria of evidence-based medicine is thus difficult. Here we try to describe the range of possible indications for botulinum toxin A and assess its therapeutic value for rare indications. The number of studies available on botulinum toxin B is still limited.

Mesh:

Substances:

Year:  2001        PMID: 11357240     DOI: 10.1007/pl00007819

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

1.  Botulinum toxin for treatment of masseteric hypertrophy.

Authors:  Andrew Che Fai Hui
Journal:  J Neurol       Date:  2002-03       Impact factor: 4.849

Review 2.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

3.  The changed image of botulinum toxin.

Authors:  V Peter Misra
Journal:  BMJ       Date:  2002-11-23

4.  Chronic eye movement induced pain and a possible role for its treatment with botulinum toxin.

Authors:  B J L Burton; S R Khan; J P Lee
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

Review 5.  Benefits and risks of pharmacological treatments for essential tremor.

Authors:  Kelly E Lyons; Rajesh Pahwa; Cynthia L Comella; Mahmood S Eisa; Rodger J Elble; Stanley Fahn; Joseph Jankovic; Jorge L Juncos; William C Koller; William G Ondo; Kapil D Sethi; Matthew B Stern; Caroline M Tanner; Ron Tintner; Ray L Watts
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.